Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

s a disease modifying treatment for multiple sclerosis (MS). Active Biotech developed laquinimod and licensed it to Teva Pharmaceutical Industries, Ltd. in June 2004. A previous 24-week Phase IIa trial conducted by Active Biotech demonstrated that oral 0.3 mg laquinimod given daily was well tolerated and reduced the formation of active lesions in RRMS. To date, 460 MS patients have received laquinimod in various clinical trials.

About MS

Multiple Sclerosis (MS) is the leading cause of neurological disability in young adults. It is estimated that 400,000 people in the United States are affected by this disease, and that over one million people are affected worldwide. MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves.

Patients with MS may experience physical symptoms and/or cognitive impairments, including weakness, fatigue, ataxia, physical dysfunction, bladder and bowel problems, sensory effects, and visual impairment. MS also has a significant impact on the sufferers' social functioning and overall quality of life.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

About Active Biotech

Active Biotech AB (ACTI.ST) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:7/30/2014)... 2014 Cynosure, Inc. (NASDAQ: ... for non-invasive and minimally invasive applications, today announced that the ... Officer and Chief Financial Officer Timothy W. Baker ... 53, will continue to serve as CFO and will take ... remains Chairman and Chief Executive Officer. "Tim ...
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... , SALT LAKE CITY, Dec. 16 ... "Company"), a medical device company engaged in the development and ... that Joe Pepper, PhD, has been appointed to the TechniScan ... "Joe has extensive experience running small to large medical devices ...
... EVANSTON, Ill., Dec. 16 Naurex Inc., a new clinical ... disorders based on its novel GFPA NMDA receptor modulators, today ... of its lead compound GLYX-13 and has successfully dosed the ... functional partial agonist (GFPA) selective modulator of the NMDA receptor, ...
Cached Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... fuel cancer as well as evolutionary changes in a ... occur randomly throughout the genome. , However, recent studies ... of multiple mutations that arise simultaneously and in close ... are frequently found in regions where chromosomal rearrangements take ... Cell Reports , may one day lead to new ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is happy ... on July 30th. After months of planning, Dr. Hamilton ... state-of-the-art suite, located only steps away from the original ... one-on-one patient comfort, shorter wait times, and generally a ... new office-suite will continue to provide the same wide ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... OAKLAND, Calif., Aug. 11 The American Heart ... Oakland and,Stanford University Medical Center $3.89 million over ... heart research center that aims to define,optimal clinical ... chronic,heart failure., The Kaiser Permanente Division of ...
... Aug. 11 Perrigo Company,(Nasdaq: PRGO ; ... chewable tablets (famotidine 10 mg; calcium carbonate 800mg;,magnesium ... under their store,brand labels. Perrigo won a successful ... to Pepcid Complete(R) marketed by,Johnson & Johnson - ...
... Inc., a,global leading manufacturer of orthodontic products and ... a full-service,orthodontic laboratory. The O2 Orthodontic Laboratory is ... Carlsbad, CA., "The O2 Orthodontic Laboratory is ... it allows the Company to further its,commitment to ...
... (GICD) and UCSF have identified a key regulatory factor ... the extensive network of arteries, veins, and capillaries that ... research, published in the latest issue of Developmental ... for a wide variety of diseases, such as heart ...
... examinations of PSA screening in younger men, a study published ... of men under age 50 reported undergoing a prostate specific ... year, yet only one in three young black men reported ... , Overall, that,s pretty good news for white men at ...
... chemical might lead to drug treatments for humans , , SUNDAY, ... of mice resistant to diet-induced obesity. , The findings ... in people. They also shed light on the brain circuitry ... energy (i.e., food) an animal takes in and how quickly ...
Cached Medicine News:Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 2Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 3Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 4Health News:Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide 2Health News:Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide 3Health News:Ortho Organizers(R) Opens a Full-Service Orthodontic Laboratory 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 3Health News:Study finds more PSA screening awareness needed among high-risk groups 2Health News:Scientists Create Mice Resistant to Obesity 2Health News:Scientists Create Mice Resistant to Obesity 3
... K-ASSAY ASO / RF / ... to be used as a ... concentration for monitoring the performance ... Rheumatoid Factor (RF), and C-Reactive ...
... of benchtop microcentrifuges with the 5424. ... aerosol-tight rotor and a unique, contoured ... ,Model 5424 expands its application range ... microcentrifuge tubes, miniprep spin columns and ...
... hand, the Jarvik 2000 pump is about the ... titanium shell sits a direct-current motor, a rotor ... moving part: a small, spinning titanium impeller that ... 7 liters per minute. Rather than take over ...
... VentrAssist is a new third generation cardiac assist ... heart transplants for patients suffering heart failure., ,It ... left ventricle of the diseased heart to help ... restoring a better quality of life. , ,It ...
Medicine Products: